Expanding Treatment Options for HER2+ Breast Cancer

Expanding Treatment Options for HER2+ Breast Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Guidelines and Approaches to HER2 Testing for Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 2: HER2+ Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 3: APHINITY and ExteNET Trials for Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 4: TRAIN-2: Anthracyclines in HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 5: KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 6: HER2+ Early Stage Breast Cancer With Residual Invasive Disease

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 7: Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 8: HER2CLIMB: Brain Metastases Data

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 9: Treatment Choice for Patient Relapsing With Brain Metastases

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 10: DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 11: SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 12: CDK4/6 Inhibitors for Triple-Positive Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

EP. 13: Impact of Recent Clinical Data on Treatment for HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Five Under 5: Top Oncology Videos for the Week of 8/31/26

CARiBOU Regimen Drives Complete Metabolic Responses in First-Line Mantle Cell Lymphoma

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer